A drop in share value experienced in early April can be attributed to competitor VitalTech partnering with AT&T to offer free telehealth services for sixty days.Additional rises in Novavax were seen after receiving $4 million in funding for vaccine development in early March from the Coalition for Epidemic Preparedness Innovations (CEPI) and having partnered with Emergent BioSolutions (EBS).